"My Funky Genetics": BRCA1/2 Mutation Carriers' Understanding of Genetic Inheritance and Reproductive Merger in the Context of New Reprogenetic Technologies

被引:21
|
作者
Werner-Lin, Allison [1 ]
Rubin, Lisa R. [2 ]
Doyle, Maya [1 ]
Stern, Rikki [3 ]
Savin, Katie [1 ]
Hurley, Karen
Sagi, Michal [4 ]
机构
[1] NYU, Silver Sch Social Work, New York, NY 10003 USA
[2] New Sch Social Res, Dept Psychol, New York, NY 10011 USA
[3] NYU, Sch Law, New York, NY 10003 USA
[4] Hadassah Med Org, Dept Genet & Metab Dis, Jerusalem, Israel
基金
美国国家卫生研究院;
关键词
BRCA mutation; preimplantation genetic diagnosis; human reproduction; couples; genetic inheritance; HEREDITARY BREAST; RISK PERCEPTION; FAMILY; DIAGNOSIS; WOMEN; CANCER; KINSHIP; DECISIONS; MEN;
D O I
10.1037/a0028434
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Deleterious mutations in the BRCA1/BRCA2 genes elevate lifetime risk of breast and ovarian cancer. Each child of a mutation-positive parent has a 50% chance of inheriting it. Preimplantation genetic diagnosis (POD) permits prospective parents to avoid the birth of a BRCA-mutation-positive child, introducing predictability into a process historically defined by chance. This investigation explored how BRCA1/2 mutation carriers understand genetic inheritance and consider a child's inheritance of a BRCA1/2 mutation, given the opportunities that exist to pursue PGD. Thirty-nine female and male BRCA1/2 mutation carriers of reproductive age were recruited from urban cancer and reproductive medical centers. Participants completed a standardized educational presentation on POD and prenatal diagnosis, with pre- and posttest assessments. An interdisciplinary team of qualitative researchers analyzed data using grounded theory techniques. Participants expressed the belief that reproduction yields children with unique genetic strengths and challenges, including the BRCA1/2 mutation, family traits for which predictive tests do not exist, and hypothetical genetic risks. Participants expressed preference for biologically related children, yet stated their genetically "well" partner's lineage would be marred through reproductive merger, requiring the well partner to assume the burden of the BRCA1/2 mutation via their children. Participants expressed diverse views of genetically "well" partners' participation in family planning and risk management decisions. Pressure to use reprogenetic technology may grow as genetic susceptibility testing becomes more widely available. Work with individuals and couples across the disease spectrum must be attuned to the ways beliefs about genetic inheritance play into reproductive decision-making.
引用
收藏
页码:166 / 180
页数:15
相关论文
共 50 条
  • [31] Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers
    Ramus, Susan J.
    Kartsonaki, Christiana
    Gayther, Simon A.
    Pharoah, Paul D. P.
    Sinilnikova, Olga M.
    Beesley, Jonathan
    Chen, Xiaoqing
    McGuffog, Lesley
    Healey, Sue
    Couch, Fergus J.
    Wang, Xianshu
    Fredericksen, Zachary
    Peterlongo, Paolo
    Manoukian, Siranoush
    Peissel, Bernard
    Zaffaroni, Daniela
    Roversi, Gaia
    Barile, Monica
    Viel, Alessandra
    Allavena, Anna
    Ottini, Laura
    Papi, Laura
    Gismondi, Viviana
    Capra, Fabio
    Radice, Paolo
    Greene, Mark H.
    Mai, Phuong L.
    Andrulis, Irene L.
    Glendon, Gord
    Ozcelik, Hilmi
    Thomassen, Mads
    Gerdes, Anne-Marie
    Kruse, Torben A.
    Cruger, Dorthe
    Jensen, Uffe Birk
    Caligo, Maria Adelaide
    Olsson, Hakan
    Kristoffersson, Ulf
    Lindblom, Annika
    Arver, Brita
    Karlsson, Per
    Askmalm, Marie Stenmark
    Borg, Ake
    Neuhausen, Susan L.
    Ding, Yuan Chun
    Nathanson, Katherine L.
    Domchek, Susan M.
    Jakubowska, Anna
    Lubinski, Jan
    Huzarski, Tomasz
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02): : 105 - 116
  • [32] Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers
    David J. Hughes
    Familial Cancer, 2008, 7 : 233 - 244
  • [33] Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers
    Barnes, D. R.
    Antoniou, A. C.
    JOURNAL OF INTERNAL MEDICINE, 2012, 271 (04) : 331 - 343
  • [34] Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: Results from ten studies
    Pan, Hong
    He, Zhongyuan
    Ling, Lijun
    Ding, Qiang
    Chen, Lin
    Zha, Xiaoming
    Zhou, Wenbin
    Liu, Xiaoan
    Wang, Shui
    CANCER EPIDEMIOLOGY, 2014, 38 (01) : 1 - 8
  • [35] Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Hughes, David J.
    FAMILIAL CANCER, 2008, 7 (03) : 233 - 244
  • [36] Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer
    Chiba, Akiko
    Hoskin, Tanya L.
    Hallberg, Emily J.
    Cogswell, Jodie A.
    Heins, Courtney N.
    Couch, Fergus J.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) : 3232 - 3238
  • [37] Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer
    Akiko Chiba
    Tanya L. Hoskin
    Emily J. Hallberg
    Jodie A. Cogswell
    Courtney N. Heins
    Fergus J. Couch
    Judy C. Boughey
    Annals of Surgical Oncology, 2016, 23 : 3232 - 3238
  • [38] Interest and Concerns Regarding Pre-Implantation Genetic Diagnosis in Female Brca1/2 Mutation Carriers
    Chu, J. N.
    Heflin, K.
    Westphal, L. M.
    FERTILITY AND STERILITY, 2012, 97 (03)
  • [39] Effect of rapid genetic testings on the rate of bilateral prophylactic mastectomy in BRCA1/2 mutation carriers.
    Cortesi, L.
    De Matteis, E.
    Razzaboni, E.
    Medici, V.
    Tazzioli, G.
    Andreotti, A.
    Federico, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
    Juliette Coignard
    Michael Lush
    Jonathan Beesley
    Tracy A. O’Mara
    Joe Dennis
    Jonathan P. Tyrer
    Daniel R. Barnes
    Lesley McGuffog
    Goska Leslie
    Manjeet K. Bolla
    Muriel A. Adank
    Simona Agata
    Thomas Ahearn
    Kristiina Aittomäki
    Irene L. Andrulis
    Hoda Anton-Culver
    Volker Arndt
    Norbert Arnold
    Kristan J. Aronson
    Banu K. Arun
    Annelie Augustinsson
    Jacopo Azzollini
    Daniel Barrowdale
    Caroline Baynes
    Heiko Becher
    Marina Bermisheva
    Leslie Bernstein
    Katarzyna Białkowska
    Carl Blomqvist
    Stig E. Bojesen
    Bernardo Bonanni
    Ake Borg
    Hiltrud Brauch
    Hermann Brenner
    Barbara Burwinkel
    Saundra S. Buys
    Trinidad Caldés
    Maria A. Caligo
    Daniele Campa
    Brian D. Carter
    Jose E. Castelao
    Jenny Chang-Claude
    Stephen J. Chanock
    Wendy K. Chung
    Kathleen B. M. Claes
    Christine L. Clarke
    J. Margriet Collée
    Don M. Conroy
    Kamila Czene
    Mary B. Daly
    Nature Communications, 12